预约演示

Immune-Onc’s antibody therapy collects second FDA orphan designation

2024-02-22

交易

免疫疗法孤儿药临床1期快速通道并购

IO-202 is a monoclonal antibody that targets leukocyte immunoglobulin-like receptor subfamily B member 4 (LILRB4), which can suppress immunity in solid tumours. Image Credit: crystal light / Shutterstock.

IO-202 Food and Drug Administration (FDA) hasleukocyte immunoglobulin-like receptor subfamily B member 4 (LILRB4)02 for the treatment of a rare blsolid tumourschronic myelomonocytic leukaemia (CMML).

IO-202 Food and Drug Administration (FDA)ck designation from the US FDA as a treatmeImmune-Onc TherapeuticsctIO-202/r) CMML in 2023. The thrare blood cancerantchronic myelomonocytic leukaemia (CMML)gnations as a treatment for acute myeloid leukaemia (AML) by the FDA in 2020 and 2022, respectively.

IO-202phan drug designations allow for an extended market exclusiUS FDAf seven years in the US and developmental incentives such as an exemption of FDA application fees and tax credits for qualified clinical testing. The fast acute myeloid leukaemia (AML)lier intFDActions with the FDA for the pursuit of accelerated approval. The status also opens chances of rolling reviews.

IO-202 is a monoclonal antibody that targets leukocyte immunoglobulin-like receptor subfamily B member 4 (LILRB4), which can suppress immunity in soFDA tumours. It also mediates the T-cell suppression and infiltration of AML cells.FDA

IO-202being investigated as a monotherapy andleukocyte immunoglobulin-like receptor subfamily B member 4 (LILRB4)therapy AbbVie/Genentech’s Venclesolid tumoursax), in a Phase I trial (NCT04372433). The study is expected tAMLnrol approximately 106 patients with either r/r AML or r/r CMML. It is expected to conclude in 2026, as per ClinicalTrial.gov.

See Also:Harmony wins orphan drug tag for pitolisant to treat Prader-Willi syndrazacytidine AbbVie Genentech r/r AML

United Therapeutics sues FDA over handlingpitolisantia’s NDAPrader-Willi syndrome

A second Phase I trial (NCT05309187) investigating IO-202 in combination with a PD-1 immune checkpoint inhibitor, MSD’s Keytruda (pembrolizumab) is also currently underway. The study enrolled approximately 200 patients with advanced solid tumours and is expected to be completed in April.

United Therapeuticses havFDAeen identified as Liquidianovation area for cancer therapy by GlobalData, with multiple companies investing to develop antibody therapies for various indications. In December 2023, AbbVie partnered with BigHat Biosciences to identify and develop antibody therapies in oncology and neuroscience indications.

GlobalData is the parent company of Pharmaceutical Technology.

Almirall is developing an interleukin-21 (IL-21)-hiIO-202g monoclonal antibody, PD-18immune checkpoint inhibitor immune checkpoint inhibitormune-infKeytruday pembrolizumabl ailments. The company acquired the therapy from Novo Nordisk last week for an uadvanced solid tumoursment and will be entitled to developmental and commercial milestones, as well as tiered royalties on future global sales.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构